Mark Wunderlich
Overview
Explore the profile of Mark Wunderlich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
99
Citations
5813
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin S, Kotliar M, Vallabh S, Ptasinska A, Assi S, Wunderlich M, et al.
Blood Adv
. 2024 Dec;
9(4):856-861.
PMID: 39705535
No abstract available.
2.
Chen Z, Zeng C, Yang L, Che Y, Chen M, Sau L, et al.
Cell
. 2024 Dec;
188(2):331-351.e30.
PMID: 39694037
Long-term durable remission in patients with B cell malignancies following chimeric antigen receptor (CAR)-T cell immunotherapy remains unsatisfactory, often due to antigen escape. Malignant B cell transformation and oncogenic growth...
3.
He X, Hawkins C, Lawley L, Phan T, Park I, Joven N, et al.
Biochim Biophys Acta Mol Basis Dis
. 2024 Nov;
1871(1):167565.
PMID: 39522891
Accumulating evidence demonstrates that the "Warburg effect" that glycolysis is enhanced even in the presence of oxygen existed in hematopoietic malignancies, contributing to extracellular acidosis. G-protein coupled receptor 68 (GPR68),...
4.
Culver-Cochran A, Hassan A, Hueneman K, Choi K, Ma A, VanCauwenbergh B, et al.
Nat Commun
. 2024 Oct;
15(1):9189.
PMID: 39448591
Acute myeloid leukemia (AML) is a deadly hematopoietic malignancy. Although many patients achieve complete remission with standard induction therapy, a combination of cytarabine and anthracycline, ~40% of patients have induction...
5.
Rondeau V, Berman J, Ling T, OBrien C, Culp-Hill R, Reisz J, et al.
Sci Transl Med
. 2024 Sep;
16(766):eadn1285.
PMID: 39321266
Acute myeloid leukemia (AML) is a devastating disease initiated and maintained by a rare subset of cells called leukemia stem cells (LSCs). LSCs are responsible for driving disease relapse, making...
6.
Chang Y, Yamamoto K, Fujino T, Wang T, Sugimoto E, Zhang W, et al.
Cell Rep
. 2024 Aug;
43(8):114536.
PMID: 39096901
Monocytic acute myeloid leukemia (AML) responds poorly to current treatments, including venetoclax-based therapy. We conducted in vivo and in vitro CRISPR-Cas9 library screenings using a mouse monocytic AML model and...
7.
Elgamal O, Fobare S, Vibhute S, Mehmood A, Vroom D, Johnson M, et al.
JCI Insight
. 2024 Apr;
9(8).
PMID: 38646934
Acute myeloid leukemia (AML) is a fatal disease characterized by the accumulation of undifferentiated myeloblasts, and agents that promote differentiation have been effective in this disease but are not curative....
8.
Fobare S, Elgamal O, Wunderlich M, Stahl E, Mehmood A, Furby C, et al.
Cancers (Basel)
. 2024 Feb;
16(3).
PMID: 38339323
Background: Acute myeloid leukemia (AML) is the malignant proliferation of immature myeloid cells characterized by a block in differentiation. As such, novel therapeutic strategies to promote the differentiation of immature...
9.
Riabov V, Xu Q, Schmitt N, Streuer A, Ge G, Bolanos L, et al.
Haematologica
. 2023 Nov;
109(5):1426-1438.
PMID: 37916386
Inhibitors of anti-apoptotic BCL-2 family proteins in combination with chemotherapy and hypomethylating agents (HMA) are promising therapeutic approaches in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). Alvocidib, a...
10.
Li Y, Xue M, Deng X, Dong L, Truong Nguyen L, Ren L, et al.
Cell Stem Cell
. 2023 Aug;
30(8):1072-1090.e10.
PMID: 37541212
TET2 is recurrently mutated in acute myeloid leukemia (AML) and its deficiency promotes leukemogenesis (driven by aggressive oncogenic mutations) and enhances leukemia stem cell (LSC) self-renewal. However, the underlying cellular/molecular...